Comparison · Selank vs Semax
Selank vs Semax: two different peptides, two different mechanisms
A careful comparison that keeps the two compounds distinct — they are not the same molecule and not interchangeable.
The short version
People constantly pair these two, so a Selank vs Semax page has to start by keeping them apart: they are different peptides with different building blocks and different jobs. Selank is a tuftsin-based heptapeptide studied mainly as an anxiolytic — a calm-the-nerves compound — that works on the brain's GABA system and on the body's own calming peptides. Semax is a different chain derived from a fragment of a stress hormone (ACTH), studied mainly as a nootropic and brain-protectant. Both came out of Russian research, and both are sold as research chemicals and are not FDA-approved. The honest summary: where their effects have been compared in the same animal model, they behave differently, not identically [11]. Below is what the literature actually supports for each, with Selank — this site's subject — cited in detail.
Two distinct molecules — never conflate them
The single most important point in any Selank vs Semax comparison is that they are not the same compound. Selank is a synthetic analog of tuftsin, the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (TP-7), built by extending tuftsin with a stabilizing C-terminal tail [2]. Semax is a separate synthetic peptide derived from a fragment of the adrenocorticotropic hormone (ACTH) family — a different parent molecule, a different sequence, and a different primary research framing (nootropic and neuroprotective rather than anxiolytic). They share a Russian developmental origin and research-chemical status, but treating them as interchangeable misreads the literature.
What the research shows for Selank
For Selank, the evidence centers on anxiety-related and immune mechanisms. It acts as a positive allosteric modulator of GABA receptor binding [1], inhibits enkephalin-degrading enzymes in human plasma (IC50 ~15 µM) [2], increases hippocampal BDNF in rats [3], and shifts GABA-pathway gene expression [4]. Russian clinical studies report an anxiolytic effect in generalized anxiety disorder without benzodiazepine-type sedation or dependence [6], alongside immunomodulatory shifts in Th1/Th2 cytokine balance [5]. This is the anxiolytic-and-immunomodulator profile that defines Selank.
Where the two have been compared directly
The cleanest direct comparison in the cited record is behavioral: in a 6-OHDA-induced Parkinsonian rat model, both Semax and Selank affected behavior, but with distinct profiles [11] — concrete evidence that the two peptides are not pharmacologically equivalent even when tested side by side. This site does not catalog Semax's own mechanism literature in depth (its ACTH-fragment biology is a separate body of work); the responsible takeaway is that each peptide has its own evidence base and its own primary use-case in research, and that the cited Selank findings here should not be transferred onto Semax or vice versa.
Using them together in research
Some in the research-use community pair the two, reasoning that an anxiolytic and a nootropic address different targets. There is no rigorous controlled human study in mainstream literature establishing the safety or efficacy of a Selank-plus-Semax combination, so any such pairing is anecdotal and unproven. As covered on Selank effects, Selank's reach across GABAergic, opioid, monoaminergic, and immune systems makes interaction effects plausible and essentially unstudied — a reason for caution that applies with extra force when stacking a second active peptide. This site makes no recommendation to combine them.